Charles G. Drake, MD, PhD

Expertise in: 
Medical Oncology, Testicular Cancer, Prostate Cancer, Kidney & Adrenal Cancer, Bladder Cancer, Internal Medicine
Accepting New Patients
Profile Headshot

Overview

Areas of Expertise / Conditions Treated

Testicular Cancer, Prostate Cancer, Kidney & Adrenal Cancer, Bladder Cancer, Medical Oncology, Internal Medicine, Clinical Research Trials, Immunology, Genitourinary Cancer

Academic Appointments

  • Professor of Medicine

Administrative Titles

  • Co-Director, Cancer Immunotherapy Programs
  • Co-leader, Tumor Biology and Microenvironment Program.

charles_g._drake_md_phd_-_director_of_genitourinary_oncology_at_cumc

Dr. Charles G. Drake is a physician-scientist with a Ph.D. in immunology, whose work focuses on understanding and fighting advanced-stage cancers with the immune system. He is known for rapidly incorporating discoveries made in the research lab into innovative clinical trials, including anti-tumor vaccines.

The Drake laboratory was the first group to show that LymphocyteActivation Gene–3 (LAG-3) is a cell surface marker for CD4 cells with regulatory function (Treg) and that blockade of LAG-3 with a monoclonal antibody could restore anti-tumor immune responses by mitigating CD8 T-cell tolerance in vivo. Further work demonstrated that LAG-3 and PD-1 were co-expressed on functionally exhausted CD8 T cells, suggesting that blockade of multiple immune checkpoints might be required to restore anti-tumor immunity. These discoveries were then translated into clinical trials.

His most recent work has focused on the body’s immunological response to radiation therapy and how immunotherapy and radiation therapy can be used in concert to treat cancer. His research has been published in prestigious journals such as the New England Journal of Medicine, Cancer Research, the Journal of Clinical Investigation, and the Journal of Clinical Oncology.

Prior to joining NewYork-Presbyterian/Columbia, Dr. Drake served as the co-director of the Cancer Immunology Program at Johns Hopkins Kimmel Cancer Center. He is also a professor of oncology, urology, and immunology. As co-director of the Prostate Cancer Multi-Disciplinary Clinic, he developed a novel transgenic model of prostate cancer, in which a unique antigen is expressed exclusively in the prostate gland and in prostate tumors.

Dr. Drake received both his bachelor’s degree in electrical engineering and his master’s degree in biomedical engineering from Rutgers University. He completed a Ph.D. program at the National Jewish Center for Immunology and Respiratory Medicine at the University of Colorado Health Sciences Center, and later earned his M.D. from the University of Colorado as part of the MSTP program. He did his internship and residency in internal medicine at the Osler Medical Service of Johns Hopkins Hospital, and did his medical oncology fellowship training in the Johns Hopkins Department of Oncology.

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Schedule an Appointment

Phone Appointments

New and Existing Patients:

Location(s)

CUMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Primary

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

AgeWell

  • Medicare Managed Care
  • Special Needs Plan

Amida Care

  • Special Needs Plan

Capital District Physician Health Plan

  • Capital District Physician Health Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • EPO
  • Medicare Managed Care
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

MVP Health Care

  • Child/Family Health Plus
  • Essential Plan
  • HMO
  • Medicaid Managed Care

Oxford Health Plans

  • Freedom
  • Liberty

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth
  • Special Needs Plan

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Credentials & Experience

Education & Training

  • MD, PhD, University of Colorado Health Sciences Center
  • Internship: Johns Hopkins Hospital
  • Residency: Johns Hopkins Hospital
  • Fellowship: Johns Hopkins Hospital

Honors & Awards

  • 2015 Resident's Teaching Award, The Brady Urological Institute at Johns Hopkins
  • 2013 Director's Teaching Award in Laboratory-Based Cancer Research; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • 2011 Society for Immunotherapy for Cancer- Volunteer Recognition Award
  • 2010 Prostate Cancer Foundation - Creativity Award
  • 2006 V Foundation - Scholar Award
  • 2006 Director's Teaching Award in Clinical Science; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • 2004 Damon Runyon - Lilly Clinical Investigator Award
  • 2001 Aventis Fellow - Johns Hopkins Department of Oncology
  • 1997 American College of Physicians Student Abstract Competition(Clinical Vignette Award)
  • 1997 Edward Stoiber Scholar Award for Outstanding Scholarship during All Four Medical School Years
  • 1996 Election to Alpha Omega Alpha (AOA) - Medical Honor Society
  • 1994 E.E. Osgood Award For Highest Ranked Abstract by a Student. Western Society for Clinical Research
  • 1993, 1994 Award For Outstanding Research; University of Colorado Student Research Forum
  • 1993 Viola Vestal Coulter Foundation Scholarship for Graduate Research
  • 1984, 1985 Deans List, Rutgers University College of Engineering
  • 1984 Eta Kappa Nu - Electrical Engineering Honor Society
America's Top Doctor

Research

Grants

A PILOT STUDY OF NEOADJUVANT COMBINATION SPARTALIZUMAB AND CANAKINUMAB PRIOR TO RADICAL NEPHRECTOMY IN PATIENTS WITH LOCALIZED CLEAR CELL RENAL CELL CARCINOMA (SPARC-1 TRIAL) (P&S Industry Clinical Trial)

May 24 2019 - May 24 2024

AN INTERNATIONAL PHASE 1/2 STUDY OF GRT-C901/GRT-R902, A NEOANTIGEN CANCER VACCINE, IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE FOR PATIENTS WITH ADVANCED SOLID TUMORS (P&S Industry Clinical Trial)

Dec 19 2018 - Dec 19 2023

AN OBSERVATIONAL FEASIBILITY STUDY FOR THE PRODUCTION OF A PATIENT-SPECIFIC NEOANTIGEN CANCER VACCINE IN PATIENTS WITH ADVANCED CANCER (P&S Industry Clinical Trial)

Nov 15 2018 - Nov 15 2023

RANDOMIZED PHASE 1B/2 STUDY OF NIVOLUMAB OR NIVOLUMAB PLUS BMS-986253 IN COMBINATION WITH INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN MEN WITH HORMONE-SENSITIVE PROSTATE CANCER (P&S Industry Clinical Trial)

Sep 27 2018 - Sep 27 2023

PROTOCOL CA027-002 ENTITLED, A PHASE 1/2A STUDY OF BMS-986253 IN COMBINATION WITH NIVOLUMAB IN ADVANCE CANCERS (SITE #0002) (P&S Industry Clinical Trial)

Mar 13 2018 - Mar 13 2023

A PHASE 1, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OFMGD009, A HUMANIZED B7-H3 X CD3 DUAL-AFFMITY RE-TARGETING (DART) PROTEIN IN PATIENTS WITH UNRESCTABLE OR METASTIC B7-H3-EXPRESSING NEOPLASMS AND NEOPLASMS WHOSE VASCULATURE EXPRESSES B7-H3 (P&S Industry Clinical Trial)

Mar 12 2018 - Mar 12 2023

A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS. (P&S Industry Clinical Trial)

Feb 22 2018 - Feb 22 2023

A PHASE 1/2 FIRST-IN-HUMAN STUDY OF BMS-986249 ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADVANCED SOLID TUMORS (P&S Industry Clinical Trial)

Feb 21 2018 - Feb 21 2023

PHASE II STUDY OF FRONT LINE THERAPY WITH NIVOLUMAB AND SALVAGE NIVOLUMAB + IPILIMUMAB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (P&S Industry Clinical Trial)

Sep 22 2017 - Sep 22 2022

PHASE 1/2A FIRST-IN-HUMAN STUDY OF BMS-986218 MONOCLONAL ANTIBODY ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADVANCED SOLID TUMORS (P&S Industry Clinical Trial)

Apr 29 2017 - Apr 29 2022

A PHASE III, MULTICENTER STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) W/ ENZALUTAMIDE VS ENZALUTAMIDE IN PTS W/ METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN SYNTHESIS INHIBITOR / INELIGIBILITY FOR/ REFUSAL OF TAXANE REGIMEN (P&S Industry Clinical Trial)

Mar 24 2017 - Mar 24 2022

ALOPECIA AREATA CENTER FOR RESEARCH TRANSLATION (AACORT) (Federal Gov)

Sep 1 2016 - Jan 31 2022

MAXIMIZING ANDROGEN DEPRIVATION IMMUNOGENICITY WITH PD-1 AND IL-8 BLOCKADE IN LETHAL PROSTATE CANCER (Private)

Oct 11 2019 - Oct 10 2021

PH1 STUDY OF T-VEC GIVEN ENDOSCOPICALLY FOR ADVANCED PANCREATIC CANCER IN 17248 (11/21/2016) (Federal Gov)

Aug 1 2018 - Jul 31 2021

CHECKPOINT INHIBITOR PD-1H (VISTA) LINKS MULTIPLE MYELOMA BONE DISEASE AND MYELOMA INDUCED IMMUNOSUPPRESSION (Private)

Jul 1 2019 - Jun 30 2021

AUGMENTING THE ADT-INDUCED IMMUNE INFILTRATE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER WITH PD-1 BLOCKADE AND DOCETAXEL (Private)

Jul 1 2019 - Jun 30 2020

MAXIMIZING ANDROGEN DEPRIVATION IMMUNOGENICITY THROUGH PD-1 AND IL-8 BLOCKADE IN CASTRATION-SENSITIVE PROSTATE CANCER (Private)

Jul 1 2019 - Jun 30 2020

CANCER CENTER SUPPORT GRANT (Federal Gov)

Jul 1 2014 - Jun 30 2020

PROSTATE CANCER CLINICAL CONSORTIUM CLINICAL RESEARCH SITE: TARGETEDTHERAPIES (Federal Gov)

Sep 20 2018 - Sep 29 2019

IMMUNOPHENOTYPING OF LICHEN PLANOPILARIS. (Federal Gov)

Sep 15 2017 - Aug 31 2019

METRONOMIC DELIVERY OF RADIOIMMUNOTHERAPY TO INDUCE A DURABLE (MRAID) ANTI-TUMOR RESPONSE IN SOLID TUMORS. (Private)

Jul 1 2018 - Jun 30 2019

TARGETING MYELOID-DERIVED SUPPRESSOR CELLS IN RENAL CELL CANCER WITH COMBINATION IL-1BETA AND PD-1 BLOCKADE (Private)

Jul 1 2018 - Jun 30 2019

HELIOS, A CYTOF SYSTEM (Federal Gov)

Mar 15 2018 - Mar 14 2019

HUMAN PROSTATE CANCER IMMUNE PHENOTYPES AND MASTER REGULATORS AFTER ANDROGEN DEPRIVATION THERAPY. (Federal Gov)

Oct 1 2018 - Dec 31 2018

ENHANCING PROSTATE CANCER IMMUNOTHERAPY THROUGH EPIGENETIC REPROGRAMMING FOR OPTIMAL ACTIVATION OF SPECIFIC EFFECTOR T-CELLS (ERASE-PCA TEAM PROPOSAL) (Private)

Dec 14 2014 - Dec 23 2017

IMMUNE-STIMULATING COMBINATORIAL THERAPY FOR PROSTATE CANCER (Federal Gov)

Nov 1 2016 - Sep 29 2017

CDK5- A NOVEL ROLE IN PROSTATE CANCER IMMUNOTHERAPY (Federal Gov)

Oct 1 2016 - Sep 29 2017